Head to head
Bergamot against Simvastatin
Bergamot is marketed as a natural statin. Fourteen randomised trials report large lipid changes including LDL down 55 mg per dL, and no trial has measured whether anyone on it has fewer heart attacks, which is exactly what the statin evidence is made of.
Column A
BergamotCitrus bergamia polyphenol extract
Fourteen randomised trials show large lipid changes, including LDL down 55 mg/dL. The effect sizes are implausibly large for a food extract, the trials are small and regionally concentrated, and no outcome trial exists.
Column B
SimvastatinSimvastatin, HMG-CoA reductase inhibitor
Fed to mice at 12 and 120 ppm from 9 months of age, simvastatin had no effect on survival in either sex. In 20,536 high-risk adults it cut all-cause mortality from 14.7 percent to 12.9 percent over five years. Both results are real and they answer different questions.
Side by side, on the facts we can check
| Attribute | Bergamot | Simvastatin |
|---|---|---|
| Category | Metabolic | Longevity |
| FDA status | Sold as a dietary supplement. Not approved to treat dyslipidaemia or anything else. | Approved and in wide use for hyperlipidaemia and cardiovascular risk reduction. No approval and no indication relating to ageing or lifespan. |
| Half-life | Not well characterised in humans. Citrus flavanones are extensively metabolised by gut microbiota and conjugated in the liver, and plasma appearance of metabolites differs substantially between people. | About 2 hours for the parent drug, though the effect on cholesterol synthesis outlasts plasma exposure, which is why it is dosed once daily. |
| Molecular weight | Not a single molecule. A standardised polyphenol extract, and products differ in flavanone content, which is the main reason results may not transfer between them. | 418.6 Da. A small molecule, not a peptide. |
| Mechanism | The bergamot polyphenolic fraction is rich in flavanones, notably brutieridin and melitidin, which carry a side chain structurally similar to the statin pharmacophore. That has led to the hypothesis of partial HMG-CoA reductase inhibition, which would make it a weak statin rather than a generic antioxidant. Other proposed actions include AMPK activation and pancreatic cholesterol ester hydrolase inhibition reducing cholesterol absorption. The statin-like mechanism remains a structural inference supported by preclinical work, not something demonstrated in humans. | A competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway, which lowers hepatic cholesterol synthesis and upregulates LDL receptors, clearing LDL from plasma. The same pathway produces isoprenoids used to prenylate small GTPases, which is the basis of the so-called pleiotropic effects, including reduced vascular inflammation, and also the most likely basis of statin-associated muscle symptoms. The geroscience hypothesis rested on those pleiotropic effects rather than on cholesterol lowering, since laboratory mice do not develop the atherosclerosis that statins prevent in people. |
| Human studies cited | 0 | 2 |
| Legal status, US | Sold as a supplement | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Bergamot and Simvastatin?
Bergamot: Fourteen randomised trials show large lipid changes, including LDL down 55 mg/dL. The effect sizes are implausibly large for a food extract, the trials are small and regionally concentrated, and no outcome trial exists. Simvastatin: Fed to mice at 12 and 120 ppm from 9 months of age, simvastatin had no effect on survival in either sex. In 20,536 high-risk adults it cut all-cause mortality from 14.7 percent to 12.9 percent over five years. Both results are real and they answer different questions.
Which has stronger research evidence, Bergamot or Simvastatin?
This database does not grade compounds. It counts what was run in people: 0 of the 1 studies cited on the Bergamot profile were human work, against 2 of 3 for Simvastatin. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Bergamot and Simvastatin FDA-approved?
Bergamot: Sold as a dietary supplement. Not approved to treat dyslipidaemia or anything else.. Simvastatin: Approved and in wide use for hyperlipidaemia and cardiovascular risk reduction. No approval and no indication relating to ageing or lifespan..
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.